Silver Book Fact

Alendronate, a bisphosphonate, has been shown to increase vertebral bone mineral density (BMD) by as much as 8% over 3-years in postmenopausal women with osteoporosis.

Wagner E, Sandhu N, Newton K, McCulloch D, et al. Effect of Improved Glycemic Control on Health Care Costs and Utilization. JAMA. 2001; 285(2): 182-189. http://jama.ama-assn.org/cgi/content/abstract/285/2/182

Reference

Title
Effect of Improved Glycemic Control on Health Care Costs and Utilization
Publication
JAMA
Publisher
JAMA
Publication Date
2001
Authors
Wagner E, Sandhu N, Newton K, McCulloch D, et al
Volume & Issue
Volume 285, Issue 2
Pages
182-189
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Human Value

Related Facts

  • 50% of Repeat Osteoporotic Fractures Could be Avoided
     
  • Alendronate, a bisphosphonate, has been shown to reduce risk of hip fracture by around 53%, clinical vertebral fracture by 45%, and wrist fracture by 30%.  
  • Reducing risk of fracture from 8% to 2% reduces the 5-year fracture incidence from approximately 34% to 10%.  
  • A recent study found that more postmenopausal women who took the drug denosumab gained at least 3% of bone mass at the hip and spine than those who took…  
  • An increase in bone mineral density (BMD) testing and osteoporosis treatment was associated with a decrease in hip fracture incidence.